Patritumab deruxtecan shows promising survival rates and manageable safety in treating leptomeningeal metastatic disease, ...

In the global, multicenter, phase 3 DESTINY-Breast09 study, Tolaney and colleagues randomly assigned 1,157 patients 1:1:1 to T-DXd plus pertuzumab (n = 383), taxane (paclitaxel or docetaxel) plus ...

Jacob Sands, MD, discusses anaging Dato-DXd toxicities like stomatitis, eye irritation, and interstitial lung disease, which ...

CHICAGO — Second-line trastuzumab deruxtecan-nxki significantly extended OS compared with paclitaxel plus ramucirumab for patients with advanced gastric cancers previously treated with ...

Trastuzumab deruxtecan, often shortened to T-DXd and marketed as Enhertu, is the most potent of those ADCs so far. Until today it sat in the second-line seat, offered after the cancer outgrew the ...

Datopotamab deruxtecan is a specifically engineered TROP2-directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by AstraZeneca and Daiichi Sankyo.

T-DXd Improves PFS in Patients With Rapid Progression on Endocrine Therapy Among patients with rapid progression (< 6 months) on first-line endocrine therapy plus cyclin-dependent kinase 4/6 ...

“Trastuzumab deruxtecan, or T-DXd, in combination with pertuzumab demonstrated a statistically significant and clinically meaningful improvement in progression-free survival, with a 44% ...

The FDA has accepted AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo's Biologics License Application for priority review for their drug datopotamab deruxtecan, also known as Dato-DXd, for the ...

The Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) for the treatment of adults with locally ...

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--The first patients have been dosed in three global, randomized phase 3 trials evaluating the efficacy and safety of datopotamab deruxtecan (Dato-DXd ...

TROPION-Lung01 is a global open label randomized phase 3 trial comparing the efficacy and safety of Dato-DXd to docetaxel in patients with previously treated advanced or metastatic non-small cell lung ...